Nelotanserin

Nelotanserin
Clinical data
Other names	APD-125
Routes of; administration	Oral
ATC code	none;
Identifiers
	IUPAC name 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea;
CAS Number	839713-36-9 ;
PubChem CID	11683556;
ChemSpider	9858284 ;
UNII	4ZA73QEW2P;
KEGG	D09645;
CompTox Dashboard (EPA)	DTXSID40232868 ;
Chemical and physical data
Formula	C18H15BrF2N4O2
Molar mass	437.245 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Brc1cnn(C)c1-c2cc(ccc2OC)NC(=O)Nc3ccc(F)cc3F;
	InChI InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26) ; Key:COSPVUFTLGQDQL-UHFFFAOYSA-N ;
	(what is this?)

Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT_2A and was under development for the treatment of insomnia.^[1] It was shown to be effective and well tolerated in clinical trials,^[2]^[3] but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.^[4] Research continues on newer analogues which may potentially be more successful.^[5] More recently, nelotanserin has been repurposed for the treatment of Lewy body disease.^[6] As of 2017, it is in phase II clinical trials for this indication.^[6]

References[]

^ Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, et al. (March 2010). "Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia". Journal of Medicinal Chemistry. 53 (5): 1923–36. doi:10.1021/jm9007328. PMID 20143782.
^ Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, et al. (December 2008). "APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia". Sleep. 31 (12): 1663–71. doi:10.1093/sleep/31.12.1663. PMC 2603489. PMID 19090322.
^ Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, et al. (January 2010). "Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia". The Journal of Pharmacology and Experimental Therapeutics. 332 (1): 281–90. doi:10.1124/jpet.109.160994. PMID 19841476. S2CID 2759858.
^ "APD125 for Insomnia". Arena Pharmaceuticals, Inc. Archived from the original on 2009-08-26.
^ Xiong Y, Ullman B, Choi JS, Cherrier M, Strah-Pleynet S, Decaire M, et al. (August 2010). "Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia". Journal of Medicinal Chemistry. 53 (15): 5696–706. doi:10.1021/jm100479q. PMID 20684606.
^ ^a ^b "Nelotanserin - Axovant Gene Therapies". Adis International Ltd. Springer Science+Business Media.

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

[1] Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, et al. (March 2010). "Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia". Journal of Medicinal Chemistry. 53 (5): 1923–36. doi:10.1021/jm9007328. PMID 20143782.

[2] Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, et al. (December 2008). "APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia". Sleep. 31 (12): 1663–71. doi:10.1093/sleep/31.12.1663. PMC 2603489. PMID 19090322.

[3] Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, et al. (January 2010). "Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia". The Journal of Pharmacology and Experimental Therapeutics. 332 (1): 281–90. doi:10.1124/jpet.109.160994. PMID 19841476. S2CID 2759858.

[4] "APD125 for Insomnia". Arena Pharmaceuticals, Inc. Archived from the original on 2009-08-26.

[5] Xiong Y, Ullman B, Choi JS, Cherrier M, Strah-Pleynet S, Decaire M, et al. (August 2010). "Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia". Journal of Medicinal Chemistry. 53 (15): 5696–706. doi:10.1021/jm100479q. PMID 20684606.

[AdisInsight-6] "Nelotanserin - Axovant Gene Therapies". Adis International Ltd. Springer Science+Business Media.

[1]

[2]

[3]

[4]

[5]

[6]

Clinical data

Other names	APD-125
Routes of administration	Oral
ATC code	none
Identifiers
IUPAC name 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
CAS Number	839713-36-9^Y
PubChem CID	11683556
ChemSpider	9858284^N
UNII	4ZA73QEW2P
KEGG	D09645
CompTox Dashboard (EPA)	DTXSID40232868
Chemical and physical data
Formula	C₁₈H₁₅BrF₂N₄O₂
Molar mass	437.245 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Brc1cnn(C)c1-c2cc(ccc2OC)NC(=O)Nc3ccc(F)cc3F
InChI InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)^N Key:COSPVUFTLGQDQL-UHFFFAOYSA-N^N
^NY (what is this?)